Acutis Diagnostics has selected the SOPHiA DDM technology from Sophia Genetics for the development of a new next-generation sequencing (NGS) test.
The new genomic assay will be created by pairing SOPHiA DDM for Hereditary Cancers Solution with Acutis’ laboratory analysis technologies.
The new test is expected to help with genomic screening for the recruitment of patients to oncology clinical studies, as well as for retrospective analyses to support the explanation of clinical outcomes and drug target discovery.
Acutis Diagnostics chief scientific officer and executive vice-president Dr Abdel Halim said: “The use of SOPHiA DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled.
“Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research.”
The NGS-based Sophia Genetics hereditary cancer solutions apply artificial intelligence and machine learning combined with patented technologies to analyse raw NGS data and offer simplified insights.
Clinical researchers can also use the technology to precisely characterise the complex mutational landscape linked with key hereditary cancer disorders.
Sophia Genetics chief revenue officer Ken Freedman said: “The new assay from Acutis Diagnostics will be designed to enable clinical researchers to work faster, and with a sound set of insights around their data, ultimately benefitting their current and future patients, as well as the industry as a whole.”
Earlier this month, Sophia Genetics also joined forces with Agilent Technologies on a comprehensive solution for cancer analysis.